Laurajean1014
<font color=blue>WISH Biggest Loser/Blue Team<br><
- Joined
- Jun 28, 2001
- Messages
- 12,828
http://www.nydailynews.com/front/story/357440p-304540c.html
Docs see a huge gain vs. breast cancer
BY PAUL H.B. SHIN
DAILY NEWS STAFF WRITER
In what is being hailed as the greatest breakthrough in breast-cancer therapy in a decade, a drug that targets a particularly aggressive type of cancer cell can cut the risk of relapse in half, two new studies show.
For women with a specific type of breast cancer - triggered by an overactive gene called HER2 - the drug Herceptin can significantly improve survival rates when used either in conjunction with or after standard chemotherapy and when the disease is detected early, researchers said.
This type of cancer accounts for 15% to 25% of all breast cancers. Because more than 200,000 American women are diagnosed with breast tumors each year, this means the drug could be used for up to 50,000 patients, and potentially save thousands of lives.
"On the basis of these results, our care of patients with HER2-positive breast cancer must change today," said Dr. Gabriel Hortobagyi, an oncologist at the University of Texas in Houston and president-elect of the American Society of Clinical Oncology.
Hortobagyi called the findings of the two independent studies, published today in the New England Journal of Medicine, "not evolutionary but revolutionary."
However, both studies also found a slightly higher risk of heart failure among women on Herceptin. And it was unclear whether that danger would grow when the drug was taken long term, researchers said.
Docs see a huge gain vs. breast cancer
BY PAUL H.B. SHIN
DAILY NEWS STAFF WRITER
In what is being hailed as the greatest breakthrough in breast-cancer therapy in a decade, a drug that targets a particularly aggressive type of cancer cell can cut the risk of relapse in half, two new studies show.
For women with a specific type of breast cancer - triggered by an overactive gene called HER2 - the drug Herceptin can significantly improve survival rates when used either in conjunction with or after standard chemotherapy and when the disease is detected early, researchers said.
This type of cancer accounts for 15% to 25% of all breast cancers. Because more than 200,000 American women are diagnosed with breast tumors each year, this means the drug could be used for up to 50,000 patients, and potentially save thousands of lives.
"On the basis of these results, our care of patients with HER2-positive breast cancer must change today," said Dr. Gabriel Hortobagyi, an oncologist at the University of Texas in Houston and president-elect of the American Society of Clinical Oncology.
Hortobagyi called the findings of the two independent studies, published today in the New England Journal of Medicine, "not evolutionary but revolutionary."
However, both studies also found a slightly higher risk of heart failure among women on Herceptin. And it was unclear whether that danger would grow when the drug was taken long term, researchers said.